Chengda Pharmaceuticals Co Ltd (301201)

Currency in CNY
35.34
+2.10(+6.32%)
Closed·
301201 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
32.5735.60
52 wk Range
26.3865.03
Key Statistics
Bid/Ask
35.34 / 35.31
Prev. Close
33.24
Open
32.93
Day's Range
32.57-35.6
52 wk Range
26.38-65.03
Volume
10.97M
Average Volume (3m)
8M
1-Year Change
28.6026%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
301201 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Earnings

Latest Release
Apr 27, 2026
EPS / Forecast
0,05 / --
Revenue / Forecast
128,24M / --
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.02%
Dividend Yield
0.60%
Industry Median 1.75%
Annualised payout
0.20
Paid annually
5-Years Growth
-
Growth Streak

301201 Income Statement

Compare 301201 to Peers and Sector

Metrics to compare
301201
Peers
Sector
Relationship
P/E Ratio
−1,519.0x23.6x−0.4x
PEG Ratio
−16.390.520.00
Price/Book
2.5x2.2x2.6x
Price / LTM Sales
11.7x3.1x3.1x
Upside (Analyst Target)
-38.6%48.8%
Fair Value Upside
Unlock12.6%5.7%Unlock

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, musculoskeletal system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates. ChengDa Pharmaceuticals Co., Ltd. was founded in 1980 and is based in Jiaxing, China.

Employees
659
Market
China

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1,78M1,17%62,76M
Other Institutional Investors
10,61M7,01%375,04M
Public Companies & Retail Investors
139,08M91,82%4,92B
Total
151,47M100,00%5,35B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Jiashan Huicheng Equity Investment Partnership Enterprise (Limited Partnership)2,20%3 328 640117 634
Jiashan Hecheng Equity Investment Partnership (Limited Partnership)1,74%2 632 00093 015

FAQ

What Is the Chengda Pharmaceuticals (301201) Stock Price Today?

The Chengda Pharmaceuticals stock price today is 35,34 CNY.

What Stock Exchange Does Chengda Pharmaceuticals Trade On?

Chengda Pharmaceuticals is listed and trades on the Shenzhen Stock Exchange.

What Is the Stock Symbol for Chengda Pharmaceuticals?

The stock symbol for Chengda Pharmaceuticals is "301201."

Does Chengda Pharmaceuticals Pay Dividends? What’s The Current Dividend Yield?

The Chengda Pharmaceuticals dividend yield is 0.6%.

What Is the Chengda Pharmaceuticals Market Cap?

As of today, Chengda Pharmaceuticals market cap is 5,35B CNY.

What Is Chengda Pharmaceuticals's Earnings Per Share (TTM)?

The Chengda Pharmaceuticals EPS (TTM) is -0,02.

From a Technical Analysis Perspective, Is 301201 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Chengda Pharmaceuticals Stock Split?

Chengda Pharmaceuticals has split 1 times.

How Many Employees Does Chengda Pharmaceuticals Have?

Chengda Pharmaceuticals has 659 employees.

What is the current trading status of Chengda Pharmaceuticals (301201)?

As of Aug 09, 2026, Chengda Pharmaceuticals (301201) is trading at a price of 35,34 CNY, with a previous close of 33,24 CNY. The stock has fluctuated within a day range of 32,57 CNY to 35,60 CNY, while its 52-week range spans from 26,38 CNY to 65,03 CNY.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.